You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

910 Results
Document
New
Mar 2025
Document
New
Mar 2025
Document
New
Mar 2025
Document
New
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib / abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Lung cancer screening through the Ontario Lung Screening Program is available for people who qualify at the following hospitals in Ontario. People...
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-3
Updated
Mar 2025
Statistical Reports
Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....
New
Feb 2025

Pages